.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK03_Rucaparib.Rucaparib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XK03_Rucaparib.Rucaparib| name: | Rucaparib |
| ATC code: | L01XK03 | route: | oral |
| n-compartments | 2 |
Rucaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of certain types of ovarian and prostate cancer. It is used especially in patients with BRCA mutations or deficiencies in homologous recombination repair. Rucaparib is currently approved and in clinical use.
Pharmacokinetic parameters reported in adults (cancer patients), following multiple oral doses of 600 mg twice daily.
Green, ML, et al., & Xiao, JJ (2022). Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. Cancer chemotherapy and pharmacology 89(5) 671–682. DOI:10.1007/s00280-022-04413-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35397664
Liao, M, et al., & Xiao, JJ (2022). Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. Clinical pharmacokinetics 61(11) 1477–1493. DOI:10.1007/s40262-022-01157-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36107395
Konecny, GE, et al., & Xiao, JJ (2021). Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Gynecologic oncology 161(3) 668–675. DOI:10.1016/j.ygyno.2021.03.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33752918